Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platform.

ABSTRACT:

Background

Plasma phospho-tau 217 (pTau217) assays can accurately detect Alzheimer's disease (AD) pathology, but clinical application is limited by the need for specialised equipment. This study tests the performance of a plasma pTau217 assay performed on the Lumipulse-G® platform, that is in widespread clinical use, for selecting patients for therapy based on β-amyloid (Aβ) status and tau staging.

Methods

Participants included 388 individuals with ¹⁸F-NAV4694 Aβ-PET and ¹⁸F-MK6240 tau-PET. Association of pTau217 with PET was examined using Spearman's correlation. Discriminative performance for Aβ and tau PET status as well as tau staging was assessed using Receiver Operating Characteristic analysis.

Findings

Plasma pTau217 had a high correlation

SUBMITTER: Feizpour A 

PROVIDER: S-EPMC11536028 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature